O	0	3	FDA
O	4	12	Approval
O	12	13	:
B-intervention	14	25	Palbociclib
O	26	29	for
O	30	33	the
O	34	43	Treatment
O	44	46	of
O	47	61	Postmenopausal
O	62	70	Patients
O	71	75	with
O	76	84	Estrogen
O	85	93	Receptor
O	93	94	-
O	94	102	Positive
O	102	103	,
O	104	108	HER2
O	108	109	-
O	109	117	Negative
O	118	128	Metastatic
O	129	135	Breast
O	136	142	Cancer
O	142	143	.

O	144	146	On
O	147	155	February
O	156	157	3
O	157	158	,
O	159	163	2015
O	163	164	,
O	165	168	the
O	169	172	FDA
O	173	180	granted
O	181	192	accelerated
O	193	201	approval
O	202	204	to
O	205	216	palbociclib
O	217	218	(
O	218	225	IBRANCE
O	225	226	,
O	227	233	Pfizer
O	234	237	Inc
O	237	238	.
O	238	239	)
O	239	240	,
O	241	243	an
O	244	253	inhibitor
O	254	256	of
O	257	263	cyclin
O	263	264	-
O	264	273	dependent
O	274	281	kinases
O	282	283	4
O	284	287	and
O	288	289	6
O	290	291	(
O	291	295	CDK4
O	296	299	and
O	300	304	CDK6
O	304	305	)
O	305	306	,
O	307	310	for
O	311	314	use
O	315	317	in
O	318	329	combination
O	330	334	with
O	335	344	letrozole
O	345	348	for
O	349	352	the
O	353	362	treatment
O	363	365	of
B-eligibility	366	380	postmenopausal
I-eligibility	381	386	women
I-eligibility	387	391	with
I-eligibility	392	400	estrogen
I-eligibility	401	409	receptor
I-eligibility	410	411	(
I-eligibility	411	413	ER
I-eligibility	413	414	)
I-eligibility	414	415	-
I-eligibility	415	423	positive
I-eligibility	423	424	,
I-eligibility	425	429	HER2
I-eligibility	429	430	-
I-eligibility	430	438	negative
I-eligibility	439	447	advanced
I-eligibility	448	454	breast
I-eligibility	455	461	cancer
O	462	464	as
O	465	472	initial
O	473	482	endocrine
O	482	483	-
O	483	488	based
O	489	496	therapy
O	497	500	for
O	501	506	their
O	507	517	metastatic
O	518	525	disease
O	525	526	.

O	527	530	The
O	531	539	approval
O	540	542	is
O	543	548	based
O	549	551	on
O	552	553	a
O	554	564	randomized
O	564	565	,
O	566	577	multicenter
O	577	578	,
O	579	583	open
O	583	584	-
O	584	589	label
O	590	595	phase
O	596	597	I
O	597	598	/
O	598	600	II
O	601	606	trial
O	607	608	(
O	608	614	PALOMA
O	614	615	-
O	615	616	1
O	616	617	)
O	618	620	in
B-total-participants	621	624	165
O	625	633	patients
O	634	644	randomized
O	645	647	to
O	648	659	palbociclib
O	660	661	(
O	661	664	125
O	665	667	mg
O	668	674	orally
O	675	680	daily
O	681	684	for
O	685	687	21
O	688	699	consecutive
O	700	704	days
O	704	705	,
O	706	714	followed
O	715	717	by
O	718	719	7
O	720	724	days
O	725	728	off
O	729	738	treatment
O	738	739	)
O	740	744	plus
O	745	754	letrozole
O	755	756	(
O	756	757	2
O	757	758	.
O	758	759	5
O	760	762	mg
O	763	769	orally
O	770	775	daily
O	775	776	)
O	777	779	or
B-control	780	789	letrozole
I-control	790	795	alone
O	795	796	.

O	797	800	The
O	801	806	phase
O	807	809	II
O	810	817	portion
O	818	820	of
O	821	824	the
O	825	830	trial
O	831	834	was
O	835	842	divided
O	843	847	into
O	848	851	two
O	852	859	cohorts
O	859	860	:
O	861	867	cohort
O	868	869	1
O	870	878	enrolled
B-intervention-participants	879	881	66
O	882	891	biomarker
O	891	892	-
O	892	902	unselected
O	903	911	patients
O	912	915	and
O	916	922	cohort
O	923	924	2
O	925	933	enrolled
B-control-participants	934	936	99
O	937	946	biomarker
O	946	947	-
O	947	955	positive
O	956	964	patients
O	964	965	.

O	966	969	The
O	970	975	major
O	976	984	efficacy
O	985	992	outcome
O	993	1000	measure
O	1001	1004	was
O	1005	1017	investigator
O	1017	1018	-
O	1018	1026	assessed
B-outcome-Measure	1027	1038	progression
I-outcome-Measure	1038	1039	-
I-outcome-Measure	1039	1043	free
I-outcome-Measure	1044	1052	survival
I-outcome-Measure	1053	1054	(
I-outcome-Measure	1054	1057	PFS
I-outcome-Measure	1057	1058	)
O	1058	1059	.

O	1060	1061	A
O	1062	1067	large
O	1068	1077	magnitude
O	1078	1080	of
O	1081	1092	improvement
O	1093	1095	in
B-outcome	1096	1099	PFS
O	1100	1103	was
O	1104	1112	observed
O	1113	1115	in
O	1116	1124	patients
O	1125	1134	receiving
O	1135	1146	palbociclib
O	1147	1151	plus
O	1152	1161	letrozole
O	1162	1170	compared
O	1171	1175	with
O	1176	1184	patients
O	1185	1194	receiving
O	1195	1204	letrozole
O	1205	1210	alone
O	1211	1212	(
O	1212	1214	HR
O	1214	1215	,
O	1216	1217	0
O	1217	1218	.
O	1218	1221	488
O	1221	1222	;
O	1223	1225	95
O	1225	1226	%
O	1227	1237	confidence
O	1238	1246	interval
O	1246	1247	,
O	1248	1249	0
O	1249	1250	.
O	1250	1253	319
O	1253	1254	-
O	1254	1255	0
O	1255	1256	.
O	1256	1259	748
O	1259	1260	)
O	1260	1261	.

O	1262	1270	Multiple
O	1271	1282	sensitivity
O	1283	1291	analyses
O	1292	1296	were
O	1297	1307	supportive
O	1308	1310	of
B-outcome	1311	1319	clinical
I-outcome	1320	1327	benefit
O	1327	1328	.

O	1329	1332	The
O	1333	1337	most
O	1338	1344	common
O	1345	1352	adverse
O	1353	1361	reaction
O	1362	1364	in
O	1365	1373	patients
O	1374	1383	receiving
O	1384	1395	palbociclib
O	1396	1400	plus
O	1401	1410	letrozole
O	1411	1414	was
O	1415	1426	neutropenia
O	1426	1427	.

O	1428	1432	This
O	1433	1440	article
O	1441	1451	summarizes
O	1452	1455	the
O	1456	1459	FDA
O	1460	1467	thought
O	1468	1475	process
O	1476	1479	and
O	1480	1484	data
O	1485	1495	supporting
O	1496	1507	accelerated
O	1508	1516	approval
O	1517	1522	based
O	1523	1525	on
O	1526	1532	PALOMA
O	1532	1533	-
O	1533	1534	1
O	1535	1539	that
O	1540	1543	may
O	1544	1546	be
O	1547	1557	contingent
O	1558	1562	upon
O	1563	1575	verification
O	1576	1579	and
O	1580	1591	description
O	1592	1594	of
O	1595	1603	clinical
O	1604	1611	benefit
O	1612	1614	in
O	1615	1618	the
O	1619	1626	ongoing
O	1627	1630	and
O	1631	1636	fully
O	1637	1644	accrued
O	1645	1657	confirmatory
O	1658	1663	trial
O	1664	1670	PALOMA
O	1670	1671	-
O	1671	1672	2
O	1672	1673	.
